Both parties will fully leverage their respective strengths in a comprehensive strategic collaboration within the field of large molecule pharmaceuticals, aiming to achieve breakthrough progress in antibody drug R&D through the application of AI technology.
The two parties will engage in deep collaboration on platform products, project optimization services, and resource expansion to promote innovation together in antibody research and development, providing pharmaceutical clients with higher-quality R&D services.
Learn MoreBioGeometry and BioMetas Join Hands to Empower Development of Novel Large Molecule Drugs
Both companies are dedicated to constructing a large multimodal model（LMM）that aligns human natural language with the language of life.
Together, they aim to lead the digital biology industry’s ecosystem construction, making AI technology platforms more efficient and convenient to aid biopharmaceutical research and development.
BioGeometry as a rising star in AI-driven large molecule biomedicine and a partner of Aliyun in the healthcare and biopharmaceutical industry, was invited to participate the 2023 Apsara Conference.
Learn MoreBioGeometry Showcased AI-Driven Biologics Platform at Apsara Conference
中文